Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…
Read More
European Commission Approves Keytruda Combination Therapy for PD-L1-Positive Platinum-Resistant Ovarian Cancer
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read More
Biocytogen and Sihuan Pharmaceutical Forge Strategic Alliance to Accelerate Advanced Therapies, Including Novel Weight Loss Treatments
The pharmaceutical landscape is poised for significant advancement as Biocytogen, a leader in antibody-based drug discovery, and Sihuan Pharmaceutical, a…
Read More
Merck KGaA Acquires JSR Life Sciences’ Chromatography Business to Bolster Biopharmaceutical Purification Capabilities
Germany-based Merck KGaA, a leading science and technology company, has officially completed its previously announced acquisition of the chromatography business…
Read More
CagriSema Surpasses Semaglutide in Efficacy and Safety for Obesity and Overweight Management, According to New Meta-Analysis
New Orleans, LA – A groundbreaking Bayesian network meta-analysis presented at the American College of Cardiology (ACC) 75th Annual Scientific…
Read More
New Data at ACC 2026 Illuminates Sotatercept’s Transformative Role in Pulmonary Arterial Hypertension Treatment Regimens
New insights unveiled at the American College of Cardiology (ACC) Annual Scientific Session & Expo 2026 are poised to reshape…
Read More
HNSCC market is expected to reach to $4.5bn across 8MM by 2034 – Pharmaceutical Technology
The global market for head and neck squamous cell carcinoma (HNSCC) therapeutics is poised for significant expansion, with projections indicating…
Read More
Eli Lilly’s Foundayo Secures FDA Approval, Challenging Novo Nordisk’s Oral Obesity Drug Dominance
The United States Food and Drug Administration (FDA) has granted approval to Eli Lilly and Company’s novel oral glucagon-like peptide-1…
Read More
Telomir Pharmaceuticals Submits Investigational New Drug Application for Telomir-1 to FDA for Advanced Triple-Negative Breast Cancer
Telomir Pharmaceuticals has taken a significant stride in its mission to combat advanced and metastatic triple-negative breast cancer (TNBC) by…
Read More
